These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25367220)

  • 21. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
    Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
    Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
    Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
    BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
    Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
    PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S; Tang Y; Yan M; Jiang W
    Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations.
    Miranda AX; Kemp J; Davidson BA; Bellomo SE; Miranda VE; Manoni A; Marchiò C; Croessmann S; Park BH; Hodges E
    BMC Genomics; 2024 May; 25(1):519. PubMed ID: 38802751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro.
    Henken FE; Banerjee NS; Snijders PJ; Meijer CJ; De-Castro Arce J; Rösl F; Broker TR; Chow LT; Steenbergen RD
    Mol Cancer; 2011 Jun; 10():71. PubMed ID: 21663621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.
    Aksamitiene E; Achanta S; Kolch W; Kholodenko BN; Hoek JB; Kiyatkin A
    Cell Signal; 2011 Nov; 23(11):1794-805. PubMed ID: 21726627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
    Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
    Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
    Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
    PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Lipid Alterations by Oncogenic
    Jung JH; Yang DQ; Song H; Wang X; Wu X; Kim KP; Pandey A; Byeon SK
    OMICS; 2023 Jul; 27(7):327-335. PubMed ID: 37463468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
    Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
    Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
    Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
    Yuan W; Stawiski E; Janakiraman V; Chan E; Durinck S; Edgar KA; Kljavin NM; Rivers CS; Gnad F; Roose-Girma M; Haverty PM; Fedorowicz G; Heldens S; Soriano RH; Zhang Z; Wallin JJ; Johnson L; Merchant M; Modrusan Z; Stern HM; Seshagiri S
    Oncogene; 2013 Jan; 32(3):318-26. PubMed ID: 22370636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
    Lauring J; Cosgrove DP; Fontana S; Gustin JP; Konishi H; Abukhdeir AM; Garay JP; Mohseni M; Wang GM; Higgins MJ; Gorkin D; Reis M; Vogelstein B; Polyak K; Cowherd M; Buckhaults PJ; Park BH
    Oncogene; 2010 Apr; 29(16):2337-45. PubMed ID: 20101210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
    Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A
    Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.